Business new tamfitronics /PRNewswire/ — Harbour BioMed (“HBM”, or the “Company”; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on oncology and immunology, today announced its interim results for the six months ended June 30, 2024. Dr. Jingsong WangFounder, Chairman and CEO of Harbour BioMed, commented, […]

Read More